AIRTON MOTA MOREIRA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
1 resultados
Resultados de Busca
Agora exibindo 1 - 1 de 1
conferenceObject TUMOR RESPONSE EVALUATION ACCORDING TO MRECIST CRITERIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH TACE-DRUG ELUTING BEADS(2012) CHAGAS, A. L.; KIKUCHI, L.; FREITAS, N. S.; SANTOS, A. C. B.; ALENCAR, R. S. S. M.; TANI, C. M.; MOREIRA, A. M.; ROCHA, M. S.; D'ALBUQUERQUE, L. A. C.; CARNEVALE, F. C.; CARRILHO, F. J.Introduction: Transarterial chemoembolization (TACE) is efficient in reduce tumoral growth and increase survival in patients with hepatocellular carcinoma (HCC). Drug eluting beads (DEB) is an embolizing device that slowly releases chemotherapy to decrease systemic toxicity during TACE. Initial studies showed that TACE-DEB is superior to conventional TACE regarding tumor response and toxicity. There is no study in our population that evaluate HCC response to TACE-DEB, according to mRECIST criteria. Objective: The aim of this study is to evaluate tumor response according to mRECIST criteria in patients with HCC treated with TACE-DEB. Methods: In the period of the study, 53 patients with HCC were treated with 65 sessions of TACE-DEB loadeD with doxorubicin 50mg. Tumor response was evaluated one month after the procedure with CT or MRI according to mRECIST criteria. Results: Median age was 62 years and 74% were male. The majority of the patients were cirrhotic (89% – CHILD A 65% and CHILD B 35%). Etilogy of liver disease was HCV in 27/53 (51%), HBV in 8/53 (15%), alcohol in 10/53 (19%) and NASH in 3/53 (6%). According to BCLC staging system, 51% was BCLC A and 49% was BCLC B. Most patients had one nodule (66%). No patient presented with extrahepatic metastasis or macroscopic vascular invasion. Tumor response according to mRECIST was possible after 60 procedures. Complete response was reached in 12/60 (20%), partial response in 31/60 (52%), stable disease in 4/60 (6.5%) and progressive disease in 13/60 (21.5%). Conclusion: In patients with compensated liver cirrhosis and HCC, TACE-DEB was efficient in induce tumor response according to mRECIST criteria, and in our study objective response (complete response + partial response) was reached in 72% os cases. Further studies are necessary to evaluate survival and predictors factors of response.